2026-04-07 晚上8:45 UTC / 路透社
作者：丹尼尔·威斯纳
2026年4月7日 晚上8:45 UTC 更新于2小时前
节点运行失败
美国马里兰州银泉市美国食品药品监督管理局总部外的标识牌，2020年8月29日。路透社/安德鲁·凯利/档案照片 购买授权权限，将在新标签页打开
- 摘要
- 案件暂停，等待特朗普政府审查
- 路易斯安那州称联邦规则破坏本州堕胎禁令
- 审查推迟至11月选举后
(2026年4月7日 路透电) 美国一名联邦法官周二暂停了路易斯安那州提起的诉讼——该诉讼试图在全美范围内限制堕胎药米非司酮的使用，同时唐纳德·特朗普政府正在对该药物的安全性进行审查。
美国路易斯安那州拉斐特的联邦地区法官戴维·约瑟夫在声明中表示，在美国食品药品监督管理局决定是否废除该规定之前，这个由共和党主导的州对2023年一项允许通过邮寄方式配送米非司酮的规则的质疑不应继续推进。该声明链接将在新标签页打开。
通过《每日案卷》新闻简报，将最新法律新闻直接发送到您的收件箱，开启您的清晨。点击此处订阅。
广告 · 滚动继续阅读
特朗普任命的约瑟夫写道：“在这个节点，符合公共利益的是完成FDA承诺的善意、基于证据且快速的审查，而非‘通过诉讼进行治理’。”
该州曾要求法官在诉讼审理期间暂停这项2023年规则，但约瑟夫驳回了这一请求。不过他表示，当案件恢复审理时，该州可以重新提出申请，而且他很可能会批准。
这位法官表示，总部位于新奥尔良的美国第五巡回上诉法院三年前已经裁定，FDA此前放宽米非司酮获取途径的规则是非法的。美国最高法院后来表示，该案的原告没有法律资格对这些规则提出质疑，但未就案件实质问题作出裁决。
广告 · 滚动继续阅读
FDA于去年启动了对米非司酮的审查。该药物于2000年首次获得批准，目前占美国堕胎案例的60%。据报道，审查工作已被推迟至11月中期选举后。
路易斯安那州总检察长、共和党人莉兹·莫里尔在一份声明中表示，她的办公室将对约瑟夫的裁决提起上诉，并要求第五巡回上诉法院暂停这项2023年规则。
自2022年美国最高法院废除堕胎的宪法权利以来，美国近一半的州已经禁止或严格限制堕胎手术。这推动了药物流产的激增，也引发了一系列围绕堕胎药物获取途径的法律纠纷。
药物流产是一种双药疗法，先服用米非司酮，再服用米索前列醇，用于终止妊娠10周内的妊娠。2023年的FDA规则取消了堕胎药物必须当面配药的要求。
莫里尔的团队于去年10月起诉FDA，称该机构无视放宽米非司酮获取途径带来的安全风险。另有五个由共和党领导的州正在就与米非司酮相关的规定提起更广泛的诉讼，包括FDA在2000年首次批准该药物的决定。
FDA要求约瑟夫暂停路易斯安那州的诉讼，以待其完成审查，同时还辩称路易斯安那州没有提起诉讼的法律资格。
路易斯安那州和德克萨斯州还起诉或传唤了其他州的医疗服务提供者，指控他们向本州居民开具米非司酮，这一做法正在考验纽约和加利福尼亚州等州的盾牌法——这些法律保护医疗服务提供者免受州外调查和起诉。
制药公司GenBioPro和丹科实验室已介入路易斯安那州的诉讼，为FDA的这项规则辩护。这些公司在法庭文件中表示，没有科学证据支持推翻FDA2023年停止要求堕胎药米非司酮当面配药的决定。
这些公司在文件中表示，米非司酮的品牌版本“米菲司酮”是丹科实验室唯一的产品，而GenBioPro的大部分收入都来自仿制药版本。
丹尼尔·威斯纳在纽约奥尔巴尼报道；亚历克西亚·加拉姆法尔维、妮娅·威廉姆斯和马修·刘易斯编辑
我们的标准：汤森路透信托原则，链接将在新标签页打开
US judge pauses Louisiana’s challenge to FDA abortion drug rule
2026-04-07 8:45 PM UTC / Reuters
By Daniel Wiessner
April 7, 2026 8:45 PM UTC Updated 2 hours ago
节点运行失败
Signage is seen outside of the Food and Drug Administration headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly/File Photo Purchase Licensing Rights, opens new tab
- Summary
- Case paused pending Trump administration review
- Louisiana says federal rule undermines state abortion ban
- Review pushed back until after November elections
April 7 (Reuters) – A federal judge on Tuesday put on hold the state of Louisiana’s lawsuit seeking to limit access to the abortion pill mifepristone nationwide while President Donald Trump’s administration conducts a review of the drug’s safety.
U.S. District Judge David Joseph in Lafayette, Louisiana, said, opens new tab the Republican-led state’s challenge to a 2023 rule allowing mifepristone to be dispensed through the mail should not proceed until the U.S. Food and Drug Administration decides whether it will repeal the regulation.
Jumpstart your morning with the latest legal news delivered straight to your inbox from The Daily Docket newsletter. Sign up here.
Advertisement · Scroll to continue
“At this juncture, it is the completion of FDA’s promised good faith, evidence-based, and expeditious review [and] not ‘government by lawsuit’ that this Court finds to be in the public interest,” wrote Joseph, a Trump appointee.
The state had asked the judge to block the 2023 rule pending the outcome of its lawsuit, which Joseph denied. But he said the state could renew its bid when the case resumes and that he would likely grant it.
The judge said that the New Orleans-based 5th U.S. Circuit Court of Appeals had already ruled three years ago that previous FDA rules easing access to mifepristone were unlawful. The U.S. Supreme Court later said that the plaintiffs in that case lacked legal standing to challenge the rules, but did not address the merits.
Advertisement · Scroll to continue
The FDA launched a review of mifepristone, which it first approved in 2000 and is now used in 60% of U.S. abortions, last year. The review has reportedly been delayed until after the November midterm elections.
Louisiana Attorney General Liz Murrill, a Republican, said in a statement that her office would appeal Joseph’s decision and ask the 5th Circuit to block the 2023 rule.
Nearly half of U.S. states have banned or severely restricted access to the procedure since the U.S. Supreme Court rolled back the constitutional right to abortion in 2022. That has driven a surge in medication abortion, which has spurred a series of legal battles over access to the drugs.
Medication abortion is a two-drug regimen consisting of mifepristone followed by misoprostol used to terminate a pregnancy within the first 10 weeks. The 2023 FDA rule eliminated a requirement that abortion drugs be dispensed in person.
Murrill’s office sued the FDA in October, claiming the agency had ignored the safety risks of easing access to mifepristone. Five other Republican-led states are pursuing broader lawsuits over regulations related to mifepristone, including the FDA’s initial approval of the drug in 2000.
The FDA asked Joseph to pause Louisiana’s case pending its review, and has also argued that Louisiana lacks legal standing to bring the case.
Louisiana and Texas have also sued or indicted healthcare providers from other states for prescribing mifepristone to their residents, testing so-called shield laws in states including New York and California that protect providers against out-of-state investigations and prosecutions.
Drug companies GenBioPro and Danco Laboratories have intervened in Louisiana’s lawsuit to defend the FDA regulation. The companies in court filings have said there is no scientific evidence that supports reversing the FDA’s 2023 decision to stop requiring the abortion drug mifepristone to be dispensed in person.
The brand-name version of mifepristone, Mifeprex, is Danco’s only product, and GenBioPro derives most of its revenue from the generic version, the companies said in the filings.
Reporting by Daniel Wiessner in Albany, New York; Editing by Alexia Garamfalvi, Nia Williams and Matthew Lewis
Our Standards: The Thomson Reuters Trust Principles., opens new tab
发表回复